Ignite Creation Date:
2025-12-24 @ 11:48 AM
Ignite Modification Date:
2025-12-31 @ 9:42 AM
Study NCT ID:
NCT06059261
Status:
RECRUITING
Last Update Posted:
2024-08-06
First Post:
2023-09-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Sponsor:
Chongqing University Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-10-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-23
First Submit QC Date:
None
Study First Post Date:
2023-09-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-04
Last Update Post Date:
2024-08-06
Last Update Post Date Type:
ACTUAL